<SEC-DOCUMENT>0001193125-23-179440.txt : 20230630
<SEC-HEADER>0001193125-23-179440.hdr.sgml : 20230630
<ACCEPTANCE-DATETIME>20230630080058
ACCESSION NUMBER:		0001193125-23-179440
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20230630
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230630
DATE AS OF CHANGE:		20230630

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MADRIGAL PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001157601
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33277
		FILM NUMBER:		231059483

	BUSINESS ADDRESS:	
		STREET 1:		200 BARR HARBOR DRIVE, SUITE 400
		CITY:			WEST CONSHOHOCKEN
		STATE:			PA
		ZIP:			19428
		BUSINESS PHONE:		404-380-9263

	MAIL ADDRESS:	
		STREET 1:		200 BARR HARBOR DRIVE, SUITE 400
		CITY:			WEST CONSHOHOCKEN
		STATE:			PA
		ZIP:			19428

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SYNTA PHARMACEUTICALS CORP
		DATE OF NAME CHANGE:	20010815
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d502542d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mdgl="http://www.madrigalpharma.com/20230630" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2023-06-30_to_2023-06-30">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2023-06-30_to_2023-06-30">0001157601</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="mdgl-20230630.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2023-06-30_to_2023-06-30"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157601</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-30</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2023-06-30_to_2023-06-30">8-K</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2023-06-30_to_2023-06-30" format="ixt:datemonthdayyearen">June&#160;30, 2023</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2023-06-30_to_2023-06-30">MADRIGAL PHARMACEUTICALS, INC.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2023-06-30_to_2023-06-30" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2023-06-30_to_2023-06-30">001-33277</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2023-06-30_to_2023-06-30">04-3508648</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File No.)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(I.R.S. Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2023-06-30_to_2023-06-30">Four Tower Bridge</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2023-06-30_to_2023-06-30">200 Barr Harbor Drive</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine3" contextRef="duration_2023-06-30_to_2023-06-30">Suite 200</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2023-06-30_to_2023-06-30">West Conshohocken</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2023-06-30_to_2023-06-30" format="ixt-sec:stateprovnameen">Pennsylvania</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2023-06-30_to_2023-06-30">19428</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive office)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2023-06-30_to_2023-06-30">(267)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2023-06-30_to_2023-06-30">824-2827</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report.)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2023-06-30_to_2023-06-30" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2023-06-30_to_2023-06-30" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2023-06-30_to_2023-06-30" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2023-06-30_to_2023-06-30" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2023-06-30_to_2023-06-30" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2023-06-30_to_2023-06-30">Common Stock, $0.0001 Par Value Per Share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2023-06-30_to_2023-06-30">MDGL</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2023-06-30_to_2023-06-30" format="ixt-sec:exchnameen">The NASDAQ Stock Market LLC</ix:nonNumeric></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;8.01 Other Events. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;30, 2023, Madrigal Pharmaceuticals, Inc. issued a press release announcing that it initiated a rolling submission of a New Drug Application to the U.S. Food and Drug Administration seeking accelerated approval of resmetirom for the treatment of NASH with liver fibrosis. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and is incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;9.01 Financial Statements and Exhibits. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td style="width:90%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Exhibit&#160;No.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d502542dex991.htm">Press release of Madrigal Pharmaceuticals, Inc. issued on June&#160;30, 2023 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL file)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:44%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:5%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:44%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">Madrigal Pharmaceuticals, Inc.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: June&#160;30, 2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian J. Lynch</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Brian J. Lynch</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Senior Vice President and General Counsel</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d502542dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g502542g0629141457836.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Madrigal Pharmaceuticals Announces Rolling Submission of New Drug Application to U.S. FDA Seeking
Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Madrigal expects to complete full submission of the New Drug Application in July 2023</I>
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CONSHOHOCKEN, PA</B>, June&nbsp;30, 2023 &#150; Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical
company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval of resmetirom for the treatment
of NASH with liver fibrosis. Madrigal has submitted the majority of the NDA to the FDA and plans to submit the remaining components in July 2023. The company will request a priority review of the NDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Resmetirom was granted Breakthrough Therapy designation in April 2023 for the treatment of patients with NASH with liver fibrosis. As a result, Madrigal was
allowed to submit individual sections of its NDA as they were completed rather than waiting until the entire application was complete. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Becky Taub, M.D.,
Chief Medical Officer and President of Research&nbsp;&amp; Development of Madrigal, stated, &#147;In the MAESTRO-NASH biopsy trial, resmetirom achieved both liver histological improvement endpoints proposed by FDA as reasonably likely to predict
clinical benefit and demonstrated a well-tolerated safety profile. We believe the positive results from MAESTRO-NASH support the potential of resmetirom to become a foundational therapy for NASH with liver fibrosis. The MAESTRO development program
will provide a robust data package to support the FDA&#146;s review of the resmetirom NDA.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paul Friedman, M.D., Chief Executive Officer of
Madrigal, stated, &#147;Madrigal is committed to addressing the needs of patients who currently have no approved treatments for NASH with liver fibrosis and the NDA submission for resmetirom is an important milestone. We look forward to working
closely with the FDA as the review process progresses.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the Resmetirom Phase 3 Registration Program for the Treatment of NASH </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madrigal is currently conducting four Phase 3 clinical trials to demonstrate the safety and efficacy of resmetirom for the treatment of NASH: MAESTRO-NASH, <FONT
STYLE="white-space:nowrap">MAESTRO-NAFLD-1,</FONT> <FONT STYLE="white-space:nowrap">MAESTRO-NAFLD-OLE,</FONT> and MAESTRO-NASH-OUTCOMES. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MAESTRO-NASH is
a multicenter, randomized, double-blind, placebo-controlled Phase 3 study of resmetirom in patients with liver biopsy-confirmed NASH and was initiated in March 2019. The portion of the study designed to support a subpart H approval enrolled more
than 1,000 patients with biopsy-proven NASH (at least half with F3 (advanced) fibrosis, the remainder F2 or F1B (moderate fibrosis) with a few earlier F1 patients, randomized 1:1:1 to receive once-daily resmetirom 80 mg, resmetirom 100 mg, or
placebo. After 52 weeks of treatment, a second liver </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g502542g0629141457836.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
biopsy is performed. The dual primary surrogate endpoints on biopsy were NASH resolution with <FONT STYLE="white-space:nowrap">&#8805;2-point</FONT> reduction in NAS (NAFLD Activity Score), and
with no worsening of fibrosis OR a <FONT STYLE="white-space:nowrap">1-point</FONT> decrease in fibrosis with no worsening of NAS. Achievement of either primary endpoint was considered a successful trial outcome. A key secondary endpoint was lowering
of <FONT STYLE="white-space:nowrap">LDL-C.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patients enrolled in the MAESTRO-NASH study (approximately 1,750) continue on therapy after the initial
<FONT STYLE="white-space:nowrap">52-week</FONT> treatment period for up to 54 months to accrue and measure hepatic clinical outcome events including progression to cirrhosis on biopsy (52 weeks and 54 months) and hepatic decompensation events, as
well as <FONT STYLE="white-space:nowrap">all-cause</FONT> mortality. This portion of the study is designed to generate confirmatory data that, if positive, may help verify resmetirom&#146;s clinical benefit and support full approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">MAESTRO-NAFLD-1</FONT> was initiated in December 2019 and the <FONT STYLE="white-space:nowrap">52-week</FONT> multicenter,
randomized, placebo-controlled Phase 3 study of resmetirom in over 1,200 patients with NAFLD, presumed NASH, has completed the double-blind arms and an open-label 100 mg arm. An additional open-label active treatment arm in patients with early
(well-compensated) NASH cirrhosis is ongoing. The primary endpoint was to evaluate the safety and tolerability of resmetirom. A separate 52 week Phase 3 clinical trial, an open-label extension study of
<FONT STYLE="white-space:nowrap">MAESTRO-NAFLD-1</FONT> <FONT STYLE="white-space:nowrap">(MAESTRO-NAFLD-OLE),</FONT> is ongoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patients in the <FONT
STYLE="white-space:nowrap">52-week</FONT> Phase 3 <FONT STYLE="white-space:nowrap">MAESTRO-NAFLD-1</FONT> study were randomized 1:1:1:1 to receive once-daily resmetirom 80 mg, resmetirom 100 mg, placebo in double-blind arms or resmetirom 100 mg in
an open-label arm. <FONT STYLE="white-space:nowrap">MAESTRO-NAFLD-1</FONT> (unlike MAESTRO-NASH), did not include a liver biopsy and represents a &#147;real-life&#148; NASH study. Patients with three metabolic risk factors were documented with NASH
or NAFLD by historical liver biopsy or noninvasive techniques. Using noninvasive measures, <FONT STYLE="white-space:nowrap">MAESTRO-NAFLD-1</FONT> was designed to provide incremental safety information to support the NASH indication as well as
provide additional data regarding clinically relevant key secondary efficacy endpoints to better characterize the potential clinical benefits of resmetirom on cardiovascular- and liver-related endpoints. The primary safety endpoint and several key
secondary endpoints were met, including <FONT STYLE="white-space:nowrap">LDL-C,</FONT> apolipoprotein B, and triglyceride lowering and reduction of liver fat as determined by <FONT STYLE="white-space:nowrap">MRI-PDFF.</FONT> Additional secondary and
exploratory endpoints were assessed including reduction in liver enzymes, FibroScan, and MRE scores, and other NASH biomarkers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Data from the <FONT
STYLE="white-space:nowrap">52-week</FONT> first 1,000 patient portion of MAESTRO-NASH, together with data from <FONT STYLE="white-space:nowrap">MAESTRO-NAFLD-1,</FONT> <FONT STYLE="white-space:nowrap">MAESTRO-NAFLD-OLE,</FONT> Phase 2 and Phase 1
data, including safety parameters, will form the basis for Madrigal&#146;s subpart H submission to FDA for accelerated approval of resmetirom for treatment of NASH with liver fibrosis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2022, Madrigal initiated MAESTRO-NASH-OUTCOMES, a randomized double-blind placebo-controlled study in approximately 700 patients with early NASH
cirrhosis to allow for noninvasive monitoring of progression to liver decompensation events. A positive outcome is expected to support the full approval of resmetirom for noncirrhotic NASH, potentially accelerating the timeline to full approval. In
addition, this study has the potential to support an additional indication for resmetirom in patients with well-compensated NASH cirrhosis. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g502542g0629141457836.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About NASH </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nonalcoholic steatohepatitis (NASH) is a more advanced form of nonalcoholic fatty liver disease (NAFLD). In the United States, NAFLD is estimated to affect
approximately 25% of the population, and approximately 25% of those will progress from NAFLD to NASH. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NASH is a leading cause of liver related mortality
and an increasing burden on healthcare systems globally. Additionally, patients with NASH, especially those with more advanced metabolic risk factors (hypertension, concomitant type 2 diabetes), are at increased risk for adverse cardiovascular
events and increased morbidity and mortality. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once NASH progresses to significant liver fibrosis (stages F2 and F3) the risk of adverse liver outcomes
increases dramatically. NASH is rapidly becoming the leading cause of liver transplantation in the U.S. There are currently no <FONT STYLE="white-space:nowrap">FDA-approved</FONT> therapies available for the treatment of NASH. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Madrigal Pharmaceuticals </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madrigal Pharmaceuticals,
Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal&#146;s lead candidate, resmetirom, is a once daily, oral,
thyroid hormone receptor (THR)-<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> selective agonist designed to target key underlying causes of NASH in the liver. For more information, visit <U>www.madrigalpharma.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This communication
includes &#147;forward-looking statements&#148; made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, that are based on Madrigal&#146;s beliefs and assumptions and on information currently available to
it, but are subject to factors beyond its control. Forward-looking statements reflect management&#146;s current knowledge, assumptions, judgment and expectations regarding future performance or events. Forward-looking statements include: all
statements that are not historical facts; statements referenced by forward-looking statement identifiers, including the examples in the paragraph below</I>; <I>resmetirom&#146;s potential to be the first specialty therapy for NASH patients with
significant liver fibrosis;</I> <I>statements concerning potential accelerated approval; statements concerning the timing of resmetirom&#146;s rolling NDA submission; and statements or references concerning - the potential efficacy and safety of
resmetirom for noncirrhotic NASH patients and cirrhotic NASH patients, possible or assumed future results of operations and expenses, business strategies and plans (including <FONT STYLE="white-space:nowrap">ex-US.</FONT> Launch/partnering plans),
research and development activities, and the timing and results associated with the future development of resmetirom, the timing and completion of projected future clinical milestone events, including enrollment, additional studies, <FONT
STYLE="white-space:nowrap">top-line</FONT> </I> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g502542g0629141457836.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<I>data and open label projections, plans, objectives, timing and support for making for making a Subpart H (Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses)
submission to FDA, projections or objectives for obtaining accelerated or full approval for resmetirom, Madrigal&#146;s primary and key secondary study endpoints for resmetirom and the potential for achieving such endpoints and projections,
demonstrating clinical benefit to support accelerated approval, the potential to support an additional indication for resmetirom in patients with well-compensated NASH cirrhosis, optimal dosing levels for resmetirom and projections regarding
potential NASH or NAFLD and potential patient benefits with resmetirom, including future NASH resolution, safety, fibrosis treatment, cardiovascular effects, lipid treatment, and/or biomarker effects with resmetirom.</I> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Forward-looking statements can be identified by terms such as &#147;accelerate,&#148; &#147;achieve,&#148; &#147;allow,&#148; &#147;anticipates,&#148;
&#147;appear,&#148; &#147;be,&#148; &#147;believes,&#148; &#147;can,&#148; &#147;confidence,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;demonstrates,&#148; &#148;design,&#148; &#147;estimates,&#148; &#147;expectation,&#148;
&#147;expects,&#148; &#147;forecasts,&#148; &#147;future,&#148; &#147;goal,&#148; &#147;help,&#148; &#147;hopeful,&#148; &#147;inform,&#148; inform,&#148; &#147;intended,&#148; &#147;intends,&#148; &#147;may,&#148; &#147;might,&#148; &#147;on
track,&#148; &#147;planned,&#148; &#147;planning,&#148; &#147;plans,&#148; &#147;positions,&#148; &#147;potential,&#148; &#147;powers,&#148; &#147;predicts,&#148; &#148;predictive,&#148; &#147;projects,&#148; &#147;seeks,&#148; &#147;should,&#148;
&#147;will,&#148; &#147;will achieve,&#148; &#147;will be,&#148; &#147;would&#148; or similar expressions and the negatives of those terms. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to: the assumptions underlying the forward-looking
statements; risks of obtaining and maintaining regulatory approvals, including, but not limited to, potential regulatory delays or rejections; risks associated with meeting the objectives of Madrigal&#146;s clinical studies, including, but not
limited to Madrigal&#146;s ability to achieve enrollment objectives concerning patient numbers (including an adequate safety database), outcomes objectives and/or timing objectives for Madrigal&#146;s studies; any delays or failures in enrollment,
and the occurrence of adverse safety events; risks related to the effects of resmetirom&#146;s mechanism of action; the achievement of enrollment objectives concerning patient number, safety database and/or timing for Madrigal&#146;s studies;
enrollment and trial conclusion uncertainties; market demand for and acceptance of our products; the potential inability to raise sufficient capital to fund ongoing operations as currently planned or to obtain financings on terms similar to those
arranged in the past; the ability to service indebtedness and otherwise comply with debt covenants; outcomes or trends from competitive studies; future topline data timing or results; the risks of achieving potential benefits in studies that
includes substantially more patients, and patients with different disease states, than prior studies; the timing and outcomes of clinical studies of resmetirom; and the uncertainties inherent in clinical testing. Undue reliance should not be placed
on forward-looking statements, which speak only as of the date they are made. Madrigal undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect
the occurrence of unanticipated events. Please refer to Madrigal&#146;s submissions filed with the U.S. Securities and Exchange Commission, or SEC, for more detailed information regarding these risks and uncertainties and other factors that may
cause actual results to differ materially from those expressed or implied. Madrigal specifically discusses these risks and uncertainties in greater detail in the section appearing in Part I, Item 1A of its Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2022, filed with the SEC on February&nbsp;23, 2023, as amended by our <FONT STYLE="white-space:nowrap">Form&nbsp;10-K/A&nbsp;filed</FONT> with the SEC on March&nbsp;3, 2023,
and as updated from time to time by Madrigal&#146;s other filings with the SEC. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Contact </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alex Howarth, Madrigal Pharmaceuticals, Inc., IR@madrigalpharma.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Christopher Frates, Madrigal
Pharmaceuticals, Inc., media@madrigalpharma.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>mdgl-20230630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 6/30/2023 3:55:00 PM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2022"
  xmlns:mdgl="http://www.madrigalpharma.com/20230630"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.madrigalpharma.com/20230630"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" namespace="http://xbrl.sec.gov/naics/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mdgl-20230630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mdgl-20230630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.madrigalpharma.com//20230630/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>mdgl-20230630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 6/30/2023 3:55:00 PM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Three</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Three</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>mdgl-20230630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 6/30/2023 3:55:01 PM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.madrigalpharma.com//20230630/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="mdgl-20230630.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.madrigalpharma.com//20230630/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine3" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g502542g0629141457836.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g502542g0629141457836.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  D *H# 2(  A$! Q$!_\0
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+HHHJ1A1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140189702522496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001157601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MADRIGAL PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3508648<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Four Tower Bridge<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">200 Barr Harbor Drive<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">West Conshohocken<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(267)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">824-2827<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.0001 Par Value Per Share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDGL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>d502542d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mdgl-20230630.xsd" xlink:type="simple"/>
    <context id="duration_2023-06-30_to_2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157601</identifier>
        </entity>
        <period>
            <startDate>2023-06-30</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2023-06-30_to_2023-06-30">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2023-06-30_to_2023-06-30"
      id="Hidden_dei_EntityCentralIndexKey">0001157601</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2023-06-30_to_2023-06-30">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2023-06-30_to_2023-06-30">2023-06-30</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2023-06-30_to_2023-06-30">MADRIGAL PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2023-06-30_to_2023-06-30">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2023-06-30_to_2023-06-30">001-33277</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2023-06-30_to_2023-06-30">04-3508648</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2023-06-30_to_2023-06-30">Four Tower Bridge</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2023-06-30_to_2023-06-30">200 Barr Harbor Drive</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="duration_2023-06-30_to_2023-06-30">Suite 200</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="duration_2023-06-30_to_2023-06-30">West Conshohocken</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2023-06-30_to_2023-06-30">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2023-06-30_to_2023-06-30">19428</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2023-06-30_to_2023-06-30">(267)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2023-06-30_to_2023-06-30">824-2827</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2023-06-30_to_2023-06-30">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2023-06-30_to_2023-06-30">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2023-06-30_to_2023-06-30">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2023-06-30_to_2023-06-30">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2023-06-30_to_2023-06-30">false</dei:EntityEmergingGrowthCompany>
    <dei:Security12bTitle contextRef="duration_2023-06-30_to_2023-06-30">Common Stock, $0.0001 Par Value Per Share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2023-06-30_to_2023-06-30">MDGL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2023-06-30_to_2023-06-30">NASDAQ</dei:SecurityExchangeName>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    "  =0-Y6'#AEZC\!   \ @
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M>::W=Y-[2:AU[D&P]_ :C1W-CQ^W_ %02P,$%     @ '4#>5B0>FZ*M
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M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  =0-Y6%(R[X.X    K @  $0
M            @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  =
M0-Y6F5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( !U WE9#9A#ND00  /$1   8
M  " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  =
M0-Y6GZ ;\+$"  #B#   #0              @ '4#   >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( !U WE:7BKL<P    !,"   +              "  ; /
M  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( !U WE8<.&7J/P$  #P"   /
M          "  9D0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  =0-Y6
M)!Z;HJT   #X 0  &@              @ $%$@  >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    "  =0-Y699!YDAD!  #/ P  $P
M        @ 'J$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"
(   T%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d502542d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.madrigalpharma.com//20230630/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d502542d8k.htm">d502542d8k.htm</File>
    <File>d502542dex991.htm</File>
    <File>mdgl-20230630.xsd</File>
    <File>mdgl-20230630_lab.xml</File>
    <File>mdgl-20230630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d502542d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 24
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d502542d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mdgl-20230630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mdgl-20230630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "mdgl-20230630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 24,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "mdgl",
   "nsuri": "http://www.madrigalpharma.com/20230630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d502542d8k.htm",
      "contextRef": "duration_2023-06-30_to_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.madrigalpharma.com//20230630/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d502542d8k.htm",
      "contextRef": "duration_2023-06-30_to_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three",
        "terseLabel": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001193125-23-179440-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-179440-xbrl.zip
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MX=:GHQ^CTV>NU>8B3;EME..F[?7Y ?I\.#SB$@>U*Q6) [7LKX@W,XX8<^U
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M.X0-[Q$V7XNPZ2/"YA>$OJW-]Y-IO19ART>$K2\(_5FG%Y+IX<<'-9(+\2*
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MBP?L<\SK,_;%/I6+1_X!4$L! A0#%     @ '4#>5J'T-JEY#@  O5X   X
M             ( !     &0U,#(U-#)D.&LN:'1M4$L! A0#%     @ '4#>
M5G[9.TYF%P  TTX  !$              ( !I0X  &0U,#(U-#)D97@Y.3$N
M:'1M4$L! A0#%     @ '4#>5FT.8=Q# P  7@L  !$              ( !
M.B8  &UD9VPM,C R,S V,S N>'-D4$L! A0#%     @ '4#>5@:='E:7!@
MN$D  !4              ( !K"D  &UD9VPM,C R,S V,S!?;&%B+GAM;%!+
M 0(4 Q0    ( !U WE8Q!Z1]U@0   XN   5              "  78P  !M
J9&=L+3(P,C,P-C,P7W!R92YX;6Q02P4&      4 !0!  0  ?S4

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
